Abstract: A packaged semiconductor chip includes a semiconductor sub strate having formed thereon: radio-frequency (RF) input and output contact pads, DC contact pads, and first and second amplifier stages. An input of the first amplifier stage is coupled with the RF input contact pad. An input and an output of the second amplifier stage are respectively coupled to an output of the first amplifier stage and the RF output contact pad. The DC contact pads and the input of the first amplifier stages are connected via an input bias coupling path. The outputs of the amplifier stages are connected via an output bias coupling path. The chip further includes a lead frame having RF input and output pins electrically coupled to the RF input and output contact pads, and input bias pins electrically coupled to the DC contact pad.

Abstract: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.

Abstract: Methods and compositions are provided for the treatment of Alzheimer's Disease (AD) by administering to a patient a therapeutically effective amount of an agent that inhibits signaling mediated by a bone morphogenetic protein type 1A receptor (BMPR-1A) or bone morphogenetic protein type 2 receptor (BMPR-2). Also provided are methods and compositions to increase the rate of neural stem cell self-renewal.

Abstract: The invention relates to the use of specific terminal deoxynucleotidyl transferase (TdT) enzymes in a method of nucleic acid synthesis, to methods of synthesizing nucleic acids, and to the use of kits comprising said enzymes in a method of nucleic acid synthesis. The invention also relates to the use of terminal deoxynucleotidyl transferases and 3?-blocked nucleotide triphosphates in a method of template independent nucleic acid synthesis.

Abstract: The invention relates to the use of specific terminal deoxynucleotidyl transferase (TdT) enzymes in a method of nucleic acid synthesis, to methods of synthesizing nucleic acids, and to the use of kits comprising said enzymes in a method of nucleic acid synthesis. The invention also relates to the use of terminal deoxynucleotidyl transferases and 3?-blocked nucleotide triphosphates in a method of template independent nucleic acid synthesis.

Abstract: Disclosed herein are methods of treating a fibrotic-mediated disorder or a collagen-mediated disorder, that include administering to a subject in need thereof a high dose of deupirfenidone, e.g., a total daily dose of up to 2500 mg. Also disclosed are interventional dosing for functionally impairing diseases and dosing for chronic disease.

Abstract: Disclosed herein is a method of treating a viral, e.g., SARS-CoV-2, respiratory disease or infection, such as COVID-19 related pneumonia, that includes administering deuterium-enriched pirfenidone, e.g., daily for 3 months or more, such that the viral respiratory disease or infection is treated. The treating is effective in preventing the development of, halting the progression of, or slowing the progression of one or more of pulmonary fibrosis, respiratory complications of the viral respiratory disease or infection, respiratory symptoms of the viral respiratory disease or infection or pulmonary dysfunction.

Abstract: Disclosed herein are methods of treating lymphedema that include administering a clinically effective amount of deupirfenidone.

Abstract: The invention relates to the use of an amine masked moiety in a method of enzymatic nucleic acid synthesis. The invention also relates to said amine masked moieties per se and a process for preparing nucleotide triphosphates comprising said amine masked moieties.

Abstract: The invention relates to the use of specific terminal deoxynucleotidyl transferase (TdT) enzymes in a method of nucleic acid synthesis, to methods of synthesizing nucleic acids, and to the use of kits comprising said enzymes in a method of nucleic acid synthesis. The invention also relates to the use of terminal deoxynucleotidyl transferases and 3?-blocked nucleotide triphosphates in a method of template independent nucleic acid synthesis.

Abstract: The invention relates to the use of specific terminal deoxynucleotidyl transferase (TdT) enzymes in a method of nucleic acid synthesis, to methods of synthesizing nucleic acids, and to the use of kits comprising said enzymes in a method of nucleic acid synthesis. The invention also relates to the use of terminal deoxynucleotidyl transferases and 3?-blocked nucleotide triphosphates in a method of template independent nucleic acid synthesis.

Abstract: The invention relates to a method of nucleic acid synthesis comprising the use of 3?-O-azidomethyl blocked nucleotide triphosphates which comprises the step of adding a capping group to any uncleaved 3?-O-azidomethyl groups and to the use of kits comprising said capping groups in a method of nucleic acid synthesis. The invention also relates to capped nucleotide triphosphates and 3?-O-azidomethyl capping groups.

Abstract: Disclosed herein are deuterium-enriched N-Aryl pyridinone compounds, optionally in combination with one or more additional therapeutic agents, pharmaceutical compositions comprising the same, methods of preparation thereof, and methods of use thereof. Such compounds and compositions are useful, for example, in treating diseases, disorders, or conditions such as edema.

Abstract: The invention relates to the use of specific terminal deoxynucleotidyl transferase (TdT) enzymes in a method of nucleic acid synthesis, to methods of synthesizing nucleic acids, and to the use of kits comprising said enzymes in a method of nucleic acid synthesis. The invention also relates to the use of terminal deoxynucleotidyl transferases and 3?-blocked nucleotide triphosphates in a method of template independent nucleic acid synthesis.

Abstract: The invention relates to the use of specific terminal deoxynucleotidyl transferase (TdT) enzymes in a method of nucleic acid synthesis, to methods of synthesizing nucleic acids, and to the use of kits comprising said enzymes in a method of nucleic acid synthesis. The invention also relates to the use of terminal deoxynucleotidyl transferases and 3?-blocked nucleotide triphosphates in a method of template independent nucleic acid synthesis.

Abstract: Disclosed herein are deuterium-enriched N-Aryl pyridinone compounds, optionally in combination with one or more additional therapeutic agents, pharmaceutical compositions comprising the same, methods of preparation thereof, and methods of use thereof. Such compounds and compositions are useful, for example, in treating diseases, disorders, or conditions such as edema.

Abstract: This application provides a system for classifying a status of anhedonia, the system including an audio data collector adapted to collect a sample of speech, and a processing module including an audio feature extractor and a classification unit, wherein the audio feature extractor extracts a plurality of acoustic features from the sample of speech, and the classification unit classifies a status of anhedonia from the plurality of acoustic features.

Abstract: The invention relates to the use of an amine masked moiety in a method of enzymatic nucleic acid synthesis. The invention also relates to said amine masked moieties per se and a process for preparing nucleotide triphosphates comprising said amine masked moieties.

Abstract: This application provides a system for classifying a status of anhedonia, the system including an audio data collector adapted to collect a sample of speech, and a processing module including an audio feature extractor and a classification unit, wherein the audio feature extractor extracts a plurality of acoustic features from the sample of speech, and the classification unit classifies a status of anhedonia from the plurality of acoustic features.

Abstract: The invention relates to a method of converting an azidomethyl ether substituent to a free hydroxyl group. The invention also relates to methods of nucleic acid synthesis and sequencing comprising the use of nucleotide triphosphates having a 3?-O-azidomethyl substituent, to kits comprising nucleotide triphosphates having a 3?-O-azidomethyl substituent and photoactivatable transition metal complex and to the use of said kits in methods of nucleic acid synthesis and sequencing.